This indicator shows the number and percent of people with diabetes receiving metformin regularly. Regular use was defined as metformin dispensed in three or more quarters in a year. 

This measure shows the percentage of people aged 65 years and over who were dispensed five, six or seven unique long-term medicines. 

This indicator shows the number and percent of people with diabetes receiving vildagliptin regularly. Regular use was defined as vildagliptin dispensed in three or more quarters in a year.

This indicator shows the number and percent of people with diabetes receiving empagliflozin regularly. Regular use was defined as empagliflozin dispensed in three or more quarters in a year.

This indicator shows the number and percent of people with diabetes admitted to hospital with the primary diagnosis of diabetic ketoacidosis one or more times in the relevant year.

This indicator shows the number and percent of people with diabetes who are admitted to hospital with hypoglycaemia as the primary diagnosis one or more times in the relevant year.

This indicator shows the number and percent of people with diabetes receiving dulaglutide regularly. Regular use was defined as dulaglutide dispensed in three or more quarters in a year.

This indicator shows the number and rate per 1,000 of the PHO-enrolled population who had received a strong opioid and had a public hospital event in the eight days prior to dispensing of a strong opioid during the calendar year. Data is presented by year (2019 to 2023), ethnic group, age, gender and health district.  

This indicator shows the number and rate per 1,000 of the PHO-enrolled population who had dispensed codeine and dihydrocodeine to them by a community pharmacy, by year (2019 to 2023), ethnic group, age group, gender.  

This measure details the rate of people dispensed a weak opioid per 1,000 population. The Institute for Healthcare Improvement classes opioids as one of four groups of medicines (along with anticoagulants, insulin and sedatives) that can cause harm to patients, even when used as intended. As with strong opioids, continuous use of a weak opioid for six weeks or more raises questions on appropriateness of use.